Format:
1 Online-Ressource (261 p)
ISBN:
9783319331973
Series Statement:
Hematologic Malignancies
Content:
Contents -- Introduction: Chronic Myeloid Leukemia (CML) in the Era of Tyrosine Kinase Inhibition -- 1: Cytogenetics of Chronic Myeloid Leukemia (CML) -- 1.1 The Discovery of the Philadelphia Chromosome (Ph) -- 1.2 The Translocation t(9 -- 22) -- 1.3 Relevance of Additional Cytogenetic Aberrations in a Ph-Positive Clone -- 1.4 Ph-Negative Clones -- 1.5 Significance of Cytogenetics for Current and Future Diagnosis and Monitoring of CML -- References -- 2: The Biology and Pathogenesis of Chronic Myeloid Leukemia -- 2.1 Clinical Overview -- 2.1.1 Diagnosis
Content:
2.1.2 CML Evolution and Prognosis -- 2.1.3 Treatment -- 2.2 The Molecular Biology of CML -- 2.2.1 The t(9 -- 22) Translocation and the BCR-ABL1 Gene -- 2.2.2 Protein Structure -- 2.2.3 The Consequence of BCR-ABL1 -- 2.3 Important Pathways Affected by BCR-ABL1 Activity -- 2.3.1 JAK/STAT -- 2.3.2 PI3K/AKT and Autophagy -- 2.3.3 Ras/MEK Pathway -- 2.3.4 Src Kinases -- 2.3.5 Crkl -- 2.3.6 Long Noncoding (lnc) RNA-BGL3 -- 2.3.7 Apoptosis Deregulation -- 2.4 CML Stem Cells -- 2.4.1 LSCs Are Refractory to TKIs -- 2.4.2 β-Catenin -- 2.4.3 Smo -- 2.4.4 PP2A-JAK2-SET -- 2.4.5 FoxO
Content:
2.4.6 Alox5 and Alox15 -- 2.4.7 Bone Marrow Microenvironment -- 2.5 Biology of Blast Crisis -- 2.5.1 BCR-ABL1 and BC-CML -- 2.5.1.1 DNA Damage/Repair -- 2.5.1.2 C/EBPα and hnRNP-E2 -- 2.5.1.3 IRF-8 -- 2.5.2 Examples of Important Pathways Involved in BC-CML -- 2.5.2.1 MYC -- 2.5.2.2 p53 -- 2.5.2.3 Musashi-2 (Msi2) -- 2.5.2.4 XPO1 -- 2.5.2.5 SIRT1 -- 2.5.2.6 ADAR1 -- 2.5.2.7 Screening for Novel BC Driver Genes -- 2.6 Concluding Remarks -- References -- 3: The Choice of First-Line Chronic Myelogenous Leukemia Treatment -- 3.1 Introduction
Content:
3.2 Second-Generation TKIs in First-Line Treatment -- 3.3 High-Dose Imatinib for First-Line Treatment -- 3.4 Combination Therapy: Imatinib Plus Interferon Alpha -- Conclusions -- References -- 4: A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia -- 4.1 Chronic Phase (CP), Accelerated Phase (AP), and Blastic Phase -- 4.2 Risk, Baseline -- 4.3 Response to Treatment -- 4.4 First-Line Treatment -- 4.5 Second-Line Treatment -- 4.6 Treatment Continuation or Discontinuation, Treatment- Free Remission (TFR), Cure
Content:
4.7 Treatment of Accelerated and Blastic Phase -- Conclusions -- References -- 5: Management of Adverse Events Associated with ATP-Competitive BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia -- 5.1 Introduction -- 5.2 Myelosuppression -- 5.3 Dermatologic Adverse Events -- 5.4 Gastrointestinal Adverse Events -- 5.5 Hepatic and Pancreatic Disorders -- 5.6 Musculoskeletal Symptoms -- 5.7 Fluid Retention -- 5.8 Pulmonary Toxicity -- 5.9 Cardiovascular Toxicity -- 5.9.1 QT Interval Prolongation -- 5.9.2 Systemic Arterial Hypertension -- 5.9.3 Congestive Heart Failure
Content:
5.9.4 Arterial Occlusion
Note:
Description based upon print version of record
Additional Edition:
9783319331980
Additional Edition:
9783319331973
Additional Edition:
Print version Hehlmann, Rüdiger Chronic Myeloid Leukemia Cham : Springer International Publishing,c2016 9783319331973
Language:
English
Keywords:
Electronic books
URL:
Volltext
(lizenzpflichtig)
Bookmarklink
